<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04848311</url>
  </required_header>
  <id_info>
    <org_study_id>NFEC-2021-073</org_study_id>
    <nct_id>NCT04848311</nct_id>
  </id_info>
  <brief_title>Indocanine Green as Tracer for Lymph Nodes Dissection in Station 253</brief_title>
  <official_title>Indocanine Green as Tracer for Lymph Nodes Dissection in Station 253 of Rectal and Sigmoid Colon Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective randomized controlled study. investigators will randomly assign&#xD;
      patients to the indocanine green (ICG) group and control (CL)group to compare the differences&#xD;
      of lymph nodes dissection in station 253 between the two groups.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ICG is a registered and FDA-approved non-specific fluorescent probe for optical imaging in&#xD;
      clinical settings. The properties of ICG ,which is a water-soluble amphiphilic molecule with&#xD;
      a molecular weight of 775 Dalton and a hydrodynamic diameter of 1.2nm ,render it an excellent&#xD;
      lymphatic contrast agents if injected into the lymphatic system. ICG near-infrared(NIR)&#xD;
      fluorescent imaging has achieved satisfactory results in the localization of sentinel lymph&#xD;
      nodes in patients with breast cancer,non-small cell lung cancer,and gastric cancer. Liang et&#xD;
      al have suggested that 253 lymph nodes dissection in rectal cancer is technically demanding&#xD;
      ,and that learning curve for laparoscopic 253 lymph nodes dissection requires minimally 20&#xD;
      procedures. Currently,it was still controversial about 253 lymph nodes dissection in rectal&#xD;
      cancer surgery. However, lymph node involvement is a major prognostic factor for survival&#xD;
      after rectal cancer surgery. Therefore, it is necessary to harvest more station 253 nodes for&#xD;
      the better long-term survival and the more precise staging.&#xD;
&#xD;
      In this study, investigators will randomly assign patients to the indocanine green (ICG)&#xD;
      group and control (CL)group. Number of harvested station 253 lymph nodes, number of positive&#xD;
      station 253 lymph nodes, will be evaluated and compared. Investigators will also evaluate&#xD;
      patients, operative time, blood loss, post-operative hospital stay and complications.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of harvested station 253 lymph nodes</measure>
    <time_frame>one week after operation</time_frame>
    <description>number of harvested station 253 lymph nodes,number of positive station 253 lymph nodes,rate of positive station 253 lymph nodes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of harvested station 251 lymph nodes</measure>
    <time_frame>one week after operation</time_frame>
    <description>number of harvested station 251 lymph nodes, number of positive station 251 lymph nodes, rate of positive station 251 lymph nodes,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of harvested station 252 lymph nodes</measure>
    <time_frame>one week after operation</time_frame>
    <description>number of harvested station 252 lymph nodes, number of positive station 252 lymph nodes , rate of positive station 252 lymph nodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of total lymph nodes harvested</measure>
    <time_frame>one week after operation</time_frame>
    <description>number of total lymph nodes harvested, number of total positive lymph nodes ,rate of total positive lymph nodes</description>
  </secondary_outcome>
  <other_outcome>
    <measure>operative time</measure>
    <time_frame>intraoperative</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>post-operative data</measure>
    <time_frame>one hour after operation</time_frame>
    <description>blood loss</description>
  </other_outcome>
  <other_outcome>
    <measure>post-operative hospital stay</measure>
    <time_frame>two weeks after operation</time_frame>
    <description>post-operative hospital stay</description>
  </other_outcome>
  <other_outcome>
    <measure>complications</measure>
    <time_frame>two weeks after operation</time_frame>
    <description>post-operative data</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Rectal Carcinoma</condition>
  <condition>Sigmoid Colon Carcinoma</condition>
  <arm_group>
    <arm_group_label>ICG group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the ICG group will undergo endoscopic injection of ICG 4 hours before surgery. The ICG powder will be dissolved in 2.5mg/ml of sterile water. ICG will be injected along the submucosa at 4 points around the primary tumor,for a total volume of 10ml.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLgroup</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in the CL group will undergo routine laparoscopic lymph nodes dissection instead of using any tracer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>lymph nodes dissection at 253 station assisted by ICG</intervention_name>
    <description>In ICG group :All patients will be subjected to laparoscopic radical resection with station 253 lymph nodes dissection by fluorescence laparoscopic.</description>
    <arm_group_label>ICG group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        (1)18-80 years of age (2)American Society of Anesthesiologists (ASA) class 1-3 (3)single&#xD;
        rectal or sigmoid colon carcinoma confirmed pathologically by endoscopic biopsy (4)planned&#xD;
        laparoscopic radical resection (5)Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. previous abdominal tumor surgery&#xD;
&#xD;
          2. women who are pregnant or breast feeding&#xD;
&#xD;
          3. emergency patients with obstruction or perforation&#xD;
&#xD;
          4. T4b cancer evaluated by CT or MRI or endoscopic ultrasonography&#xD;
&#xD;
          5. pelvic or distant metastasis&#xD;
&#xD;
          6. T1 cancer planned local excision&#xD;
&#xD;
          7. allergic constitution patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Yan, M.D,Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanfang Hospital of Southern Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Yan, M.D,Ph.D</last_name>
    <phone>13825066546</phone>
    <email>yanjunfudan@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Yan, M.D.,Ph.D</last_name>
      <phone>086-13825066546</phone>
      <email>yanjunfudan@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>April 12, 2021</study_first_submitted>
  <study_first_submitted_qc>April 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ICG</keyword>
  <keyword>253 lymph nodes</keyword>
  <keyword>rectal carcinoma</keyword>
  <keyword>sigmoid colon carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

